24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

Name: 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
Published: 2014
License: Public Domain

AstraZeneca · 2014

ClinicalTrials.gov · Datasets · License: Public Domain · 2014

Open Source ↗

type-2-diabetes type-2-diabetes-mellitus

type 2 diabetes mellitus, saxagliptin, acarbose, type 2 diabetes, metformin, interventional, phase4

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

Related documents